Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of enzalutamide and TMPRSS2-ETS fusion as a predictive biomarker in metastatic castration-resistant prostate cancer
2014-003192-28Phase 2Completed
- Sponsor
- SOGUG
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SOGUG. Primary endpoint: PSA progression-free survival. Started Nov 2014; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2014-003192-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003192-28.